普瑞巴林
普瑞巴林(Pregabalin),是一种治疗癫痫、神经痛、纤维肌痛、广泛性焦虑症[1][2]的药物。
化学数据 | |
---|---|
化学式 | C8H17NO2 |
摩尔质量 | 159.23 g·mol−1 |
识别信息 | |
IUPAC名称 | (3S)S)-3-(氨基甲基)-5-甲基己酸 |
CAS号 | |
PubChem CID |
药理学
普瑞巴林是神经递质γ-氨基丁酸的衍生物,[3] 也是一种强效的加巴喷丁类物质,但它并不与任何γ-氨基丁酸受体结合,而是通过抑制钙通道发挥作用。[4][5]它是某些电压依赖性钙通道(VDCCs)的辅助α2δ亚基位点的配体,从而作为含α2δ亚基的电压依赖性钙通道的抑制剂。[4] [6]它与α2δ1以及α2δ2这两个亚基结合,并在这两个位点上表现出了相似的亲和力,因此普瑞巴林缺乏α2δ亚基的选择性,[4]但具有电压依赖性钙通道的α2δ亚基选择性。[6] [7] 虽然普瑞巴林不与任何γ-氨基丁酸受体结合,也不会转换为γ-氨基丁酸或其他γ-氨基丁酸受体激动剂,也不直接调节γ-氨基丁酸的转运或代谢,[5][6]但它会增加L-谷氨酸脱羧酶(GAD)在大脑中的表达,[8][9] [10] 而此酶是用于合成γ-氨基丁酸的酶,因此可能由于大脑内γ氨基丁酸水平升高造成一些γ-氨基丁酸能的作用。但目前没有证据可以说明普瑞巴林的作用是除了抑制含α2δ亚基的电压依赖性钙通道介导的。[6] [11] 因此,普瑞巴林对其的抑制作用似乎是它抗惊厥、镇痛和抗焦虑效果的原因。[6][11]
在一项研究中发现,普瑞巴林对含α2δ亚基的电压依赖性钙通具有比加巴喷丁高6倍的亲和力,[12][13]而在另一项研究中发现,普瑞巴林和加巴喷丁对人类重组α2δ1亚基具有差不多的亲和力(Ki分别为32 nM和40 nM)。[14]在任何情况下,普瑞巴林作为镇痛药的效力是加巴喷丁的2~4倍,[3][15]在动物身上作为抗惊厥药时的效力似乎是加巴喷丁的3~10倍。[3][15]
滥用
普瑞巴林因其中枢抑制的特性时常被滥用,通常会使用至少一次300mg或更高的剂量。普瑞巴林在过量时可能具有成瘾性和戒断反应。
參考文献
- ↑ Frampton, JE (September 2014). "Pregabalin: a review of its use in adults with generalized anxiety disorder". CNS Drugs. 28 (9): 835–54. doi:10.1007/s40263-014-0192-0. PMID 25149863.
- ↑ "Pregabalin". The American Society of Health-System Pharmacists. Archived from the original on 2020-08-09. Retrieved 2015-10-23.
{{cite web}}
: Unknown parameter|dead-url=
ignored (|url-status=
suggested) (help) - ↑ 3.0 3.1 3.2 Bryans JS, Wustrow DJ (March 1999). "3-substituted GABA analogs with central nervous system activity: a review". Medicinal Research Reviews. 19 (2): 149–177. doi:10.1002/(SICI)1098-1128(199903)19:2<149::AID-MED3>3.0.CO;2-B. PMID 10189176. S2CID 38496241.
- ↑ 4.0 4.1 4.2 Calandre EP, Rico-Villademoros F, Slim M (November 2016). "Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use". Expert Review of Neurotherapeutics. 16 (11): 1263–1277. doi:10.1080/14737175.2016.1202764. PMID 27345098. S2CID 33200190.
- ↑ 5.0 5.1 Uchitel OD, Di Guilmi MN, Urbano FJ, Gonzalez-Inchauspe C (2010). "Acute modulation of calcium currents and synaptic transmission by gabapentinoids". Channels. 4 (6): 490–496. doi:10.4161/chan.4.6.12864. PMID 21150315.
- ↑ 6.0 6.1 6.2 6.3 6.4 Sills GJ (February 2006). "The mechanisms of action of gabapentin and pregabalin". Current Opinion in Pharmacology. 6 (1): 108–113. doi:10.1016/j.coph.2005.11.003. PMID 16376147.
- ↑ Benzon HM, Rathmell JP, Wu CL, Turk DC, Argoff CE, Hurley RW (September 11, 2013). Practical Management of Pain. Elsevier Health Sciences. p. 1006. ISBN 978-0-323-17080-2.
- ↑ Lin GQ, You QD, Cheng JF, eds. (August 8, 2011). Chiral Drugs: Chemistry and Biological Action. John Wiley & Sons. p. 88. ISBN 9781118075630. Archived from the original on April 25, 2022. Retrieved August 17, 2016 – via Google Books.
- ↑ Li Z, Taylor CP, Weber M, Piechan J, Prior F, Bian F, et al. (September 2011). "Pregabalin is a potent and selective ligand for α(2)δ-1 and α(2)δ-2 calcium channel subunits". European Journal of Pharmacology. 667 (1–3): 80–90. doi:10.1016/j.ejphar.2011.05.054. PMID 21651903. Archived from the original on October 21, 2020. Retrieved October 20, 2020.
- ↑ Sze PY (1979). "L-Glutamate Decarboxylase". GABA—Biochemistry and CNS Functions. Advances in Experimental Medicine and Biology. Vol. 123. pp. 59–78. doi:10.1007/978-1-4899-5199-1_4. ISBN 978-1-4899-5201-1. PMID 390996.
- ↑ 11.0 11.1 Stahl SM, Porreca F, Taylor CP, Cheung R, Thorpe AJ, Clair A (June 2013). "The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?". Trends in Pharmacological Sciences. 34 (6): 332–339. doi:10.1016/j.tips.2013.04.001. PMID 23642658.
- ↑ Baidya DK, Agarwal A, Khanna P, Arora MK (July 2011). "Pregabalin in acute and chronic pain". Journal of Anaesthesiology Clinical Pharmacology. 27 (3): 307–314. doi:10.4103/0970-9185.83672. PMC 3161452. PMID 21897498.
- ↑ McMahon SB (2013). Wall and Melzack's textbook of pain (6th ed.). Philadelphia, PA: Elsevier/Saunders. p. 515. ISBN 9780702040597.
- ↑ Taylor CP, Angelotti T, Fauman E (February 2007). "Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery". Epilepsy Research. 73 (2): 137–150. doi:10.1016/j.eplepsyres.2006.09.008. PMID 17126531. S2CID 54254671. Archived from the original on October 23, 2020. Retrieved October 19, 2020.
- ↑ 15.0 15.1 Lauria-Horner BA, Pohl RB (April 2003). "Pregabalin: a new anxiolytic". Expert Opinion on Investigational Drugs. 12 (4): 663–672. doi:10.1517/13543784.12.4.663. PMID 12665421. S2CID 36137322.